1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Fujifilm Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FUJIFILM Healthcare Americas Corporation Awarded Exclusive Contract for Surgical C-Arm Systems from the U.S. Army and Defense Logistics Agency (DLA)

12/20/2021 | 09:30am EDT

Lexington, Mass., USA, Dec. 20, 2021 (GLOBE NEWSWIRE) --  FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic imaging and medical informatics solutions, today announced that it has been awarded a 4-year contract for its innovative surgical C-arm systems from the U.S. Army and Defense Logistics Agency (DLA).

Under the contract, Fujifilm will outfit multiple U.S. Army medical treatment facilities with the company’s Persona C mobile fluoroscopy system, an advanced surgical C-arm designed for imaging across a broad range of diagnostic imaging and minimally invasive surgical procedures. The first C-arm system delivery and installation is slated in early Q1 of 2022, followed by additional installations throughout the year.

“Fujifilm is honored to be awarded another significant contract from the DLA this year, as it speaks to the confidence and level of trust military officials place in our cutting-edge technology,” said Lou Cavallaro, Director, Government Business Sales, FUJIFILM Healthcare Americas Corporation. “This achievement reflects Fujifilm’s ongoing commitment to developing the highest quality imaging technology to enhance patient safety and care.”

Fujifilm’s contract was granted after a detailed evaluation and comparison of numerous competitive C-arm technologies. Following a comprehensive assessment of each manufacturer’s system technology, functionality, adaptability, service support infrastructure and cybersecurity compliance, Fujifilm was selected as the singular vendor that best met or exceeded the U.S. Army’s exacting standards and demanding criteria.

In August 2021, the company was awarded a 10-year sole source contract for its innovative digital radiography (DR) systems from the U.S. Navy and Defense Logistics Agency (DLA). Additionally, Fujifilm has been granted by various branches of the U.S. Federal Government, including a 10-year DOD Digital Imaging Network-PACS (DIN-PACS) IV contract as well as a 10-year Joint DLA/VA Radiology and Imaging Systems Contract.

About Fujifilm

FUJIFILM Healthcare Americas Corporation is a leading innovator in diagnostic and enterprise imaging solutions designed to meet the evolving needs of healthcare across prevention, diagnosis, and treatment. Fujifilm’s medical imaging portfolio includes solutions for digital radiography, mammography, computed tomography, magnetic resonance imaging, ultrasound, endoscopy, and endosurgery. The Synapse® Enterprise Imaging portfolio provides healthcare professionals with the imaging and data access needed to deliver a complete patient record. REiLI®, Fujifilm’s artificial intelligence initiative, combines Fujifilm’s rich image -processing heritage with cutting-edge AI innovations to inspire a new tier of clinical confidence. The In-Vitro Diagnostic portfolio provides the golden standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories across the country and diagnostic chemicals for OEM white labeling products. The company is headquartered in Lexington, Massachusetts. For more information please visit healthcaresolutions-us.fujifilm.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com


Marissa ConfredoFUJIFILM Holdings America Corporation
914-343-4761
marissa.confredo@fujifilm.com
Source: FUJIFILM Holdings America Corporation

2021 GlobeNewswire, Inc., source Press Releases

All news about FUJIFILM HOLDINGS CORPORATION
05/24FUJIFILM Cellular Dynamics Launches Parkinson's Disease iCell DopaNeurons featuring LRR..
AQ
05/18Fujifilm Provides Education Advancement Opportunities for Gastroenterologists and Endos..
AQ
05/17Fujifilm Showcases New Endoscopy Innovations for the Detection, Diagnosis, and Treatmen..
AQ
05/16RAYUS Radiology Partners with Fujifilm and selects Synapse® Enterprise Information Syst..
AQ
05/16RAYUS Radiology Partners with Fujifilm and Selects Synapse® Enterprise Information Syst..
CI
05/16FUJIFILM VisualSonics Launches the New Multi-modal Vevo F2 Imaging Platform for Preclin..
AQ
05/11Fujifilm's Attributable Net Income Grows 16.5% in FY22
MT
05/02Fujifilm Selected as Platinum Partner of the National Rural Health Association
AQ
04/27Fujifilm Awarded Pacific Air Force/Navy Order from the U.S. Department of Defense and D..
AQ
04/27Fujifilm Awarded Pacific Air Force/Navy Order from the U.S. Department of Defense and D..
CI
More news
Financials
Sales 2022 2 514 B 19 744 M 19 744 M
Net income 2022 187 B 1 466 M 1 466 M
Net Debt 2022 136 B 1 072 M 1 072 M
P/E ratio 2022 14,6x
Yield 2022 1,63%
Capitalization 2 726 B 21 405 M 21 405 M
EV / Sales 2022 1,14x
EV / Sales 2023 1,03x
Nbr of Employees 73 275
Free-Float 74,1%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
Fujifilm Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 6 801,00 JPY
Average target price 9 838,46 JPY
Spread / Average Target 44,7%
EPS Revisions
Managers and Directors
Teiichi Goto President, CEO & Representative Director
Kenji Sukeno Chairman
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
FUJIFILM HOLDINGS CORPORATION-19.97%21 491
ABBOTT LABORATORIES-19.58%198 189
MEDTRONIC PLC2.02%141 586
BECTON, DICKINSON AND COMPANY2.60%71 882
HOYA CORPORATION-19.84%39 348
BAXTER INTERNATIONAL INC.-12.41%37 860